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Pulmonary arterial hypertension (PAH) is a progressive debili-
tating condition characterized by increased resistance in the 
pulmonary arterial circulation. Clinically, PAH is defined as a 
resting mean pulmonary artery pressure ≥25 mm Hg with a 
normal pulmonary venous pressure ≤15 mm Hg.1 PAH may 
have diverse etiology but a common pathogenesis that results in 
pulmonary vascular remodeling with proliferation and hyper-
trophy of pulmonary arterial smooth muscle cells, vasoconstric-
tion, endothelial dysfunction, and thrombosis in situ.1 Several 
vascular changes are associated with PAH, including downregu-
lation of prostacyclin synthase2 resulting in a relative deficiency 
of prostacyclin (PGI2),3 overexpression of endothelin-1,4 and 
downregulation of nitric oxide production with a decrease in 
intracellular cyclic guanosine monophosphate expression.5
Although prognosis for PAH remains poor, major improve-
ments have been made in disease management with the introduc-
tion of therapeutic agents targeting various affected pathways.6 
Current treatments of PAH include parenteral prostanoids (epo-
prostenol, treprostinil, and ilioprost), oral endothelin receptor 
antagonists (bosentan, sitaxentan, and ambrisentan), and oral 
inhibitors of phosphodiesterase-5 (sildenafil and tadalafil).1 
To date, there is no compelling evidence for one class of drugs 
being superior over another, but it is generally accepted that pros-
tanoids, which are difficult to administer and maintain, are used 
in patients with severe disease or in those who have failed to 
respond to other therapies. Therefore, oral endothelin receptor 
antagonists and phosphodiesterase-5 inhibitors often become a 
first-line treatment in mild-to-moderate PAH.
Bosentan is an oral dual endothelin receptor antagonist 
approved for treatment of PAH patients with World Health 
Organization class II–IV symptoms. Bosentan is usually initi-
ated at a dose of 62.5 mg twice daily and increased to 125 mg 
twice daily after 4 weeks of treatment. The pharmacokinetics 
of bosentan has been well described.7 After oral administra-
tion, bosentan is absorbed with an absolute bioavailability of 
50%, reaching peak plasma concentrations in about 3–4 h. 
Bosentan is taken up from the blood into the liver by organic 
anion-transporting polypeptide (OATP)1B1 and OATP1B3, 
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and metabolized by cytochrome P450 isozymes(CYP)3A4 and 
CYP2C9 to three major metabolites, one of which (Ro 48–5033) 
may contribute to up to 20% of total drug response. Bosentan 
is mainly cleared by hepatic metabolism, with an elimination 
half-life of approximately 4–5 h. Bosentan has been shown to 
significantly improve exercise ability and reduce the rate of 
clinical worsening in PAH patients.8,9 Unfortunately, exposure-
dependent liver toxicity, manifesting in the form of increased 
activity of aminotransferases in 10–12% of treated patients,9,10 
limits bosentan use.
The possible mechanisms of bosentan-induced liver 
injury include a decrease in hepatic uptake of bosentan by 
OATP1B1/1B3, the subsequent increase in systemic expo-
sure11,12 as well as a decrease in activity of CYP enzymes, and 
the subsequent increase in both systemic and intrahepatic expo-
sure.13,14 There is also evidence that bosentan inhibits hepatic 
canalicular efflux transporters, such as the bile salt export pump 
(BSEP) and multidrug resistance–associated protein 2 (MRP2), 
which are responsible for bile acid excretion, leading to intrahe-
patic bile acid accumulation and consequently liver damage.15–17 
The latter mechanism might be independent or sequential to 
increased bosentan exposure. The majority of studies have 
focused on drug–drug interactions resulting in inhibition of 
liver uptake transporters or CYP enzymes. To date, no attempts 
have been made to study the influence of naturally occurring 
reduced-function single-nucleotide polymorphisms (SNPs) in 
genes encoding the proteins involved in bosentan disposition 
(CYP2C9, CYP3A4, OATP1B1/1B3, BSEP, and MRP2).
The current study was designed to examine associations 
between bosentan-induced liver injury and reduced-func-
tion SNPs in genes encoding CYP2C9, CYP3A4, OATP1B1, 
OATP1B3, BSEP, and MRP2. Putative genetic markers of 
bosentan-induced liver injury could be further investigated as 
biomarkers for stratification of PAH patients for appropriate 
treatment regimens.
RESULTS
Cohort analysis
The original study cohort consisted of 92 ethnically diverse PAH 
patients. The majority of patients were Caucasians (61%), with 
smaller numbers of Asians (15%), Hispanics (15%), and African 
Americans (5%). There was no association of race with either 
change in alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) levels or DILI (data not shown). Only the 
Caucasian group (n = 56) was large enough for genetic associa-
tion analysis. Characteristics of the Caucasians included in the 
current analysis are shown in Table 1. The cohort, consisting 
mostly of women (71%), had an average age of 51 ± 13 years 
and mean body mass index of 30.8 ± 7.6 kg/m2. Less than 10% of 
the patients had a history of previous liver disease. The range of 
cumulative bosentan exposure was large, reflecting interpatient 
differences in the time of bosentan therapy. More than half of 
the patients (57.1%) were coadministered an OATP1B1 inhibi-
tor (sildenafil in most cases). Comedications that were known 
inhibitors of CYP2C9, CYP3A4, and MRP2 were used in 5.3%, 
8.9%, and 3.6% of patients, respectively.
Associations between candidate SNPs and increases in ALT 
and AST activity in Caucasian PAH patients treated with 
bosentan
In a univariate linear regression analysis, body mass index 
showed a trend for negative correlation with ALT and AST 
increase (β = 0.96, P = 0.06; β = 0.98, P = 0.13, respectively). 
A single SNP in CYP2C9 (CYP2C9*2, rs1799853) showed a 
trend for association with ALT and AST increase in univari-
ate analysis (Table 2) and was further tested in multivariate 
analysis. In a multivariate model adjusted for body mass index, 
CYP2C9*2 remained significantly associated with increases in 
ALT (β = 2.16, P = 0.024; Figure 1a) and AST (β = 1.92; P = 
0.016; Figure 1b) activity.
Associations between candidate SNPs and DILI in Caucasian 
PAH patients treated with bosentan
In univariate logistic regression (continuous variables) or by 
Fisher’s exact test (dichotomous variables), none of the clinical 
covariates showed any trend for association with occurrence 
of DILI (Table 3), whereas a SNP in SLCO1B1 (rs11045819) 
showed a trend for association with bosentan-induced liver 
injury (Table 3). CYP2C9*2 was the only polymorphism sig-
nificantly associated with occurrence of DILI (odds ratio 95% 
confidence interval = 2.29–∞; P = 0.003; Table 3 and Figure 2). 
Multivariate analysis was not performed due to the small sizes 
of the cohort and the DILI group.
In vitro bosentan metabolite identification and functional 
characterization of CYP2C9*1, CYP2C9*2, and CYP2C9*3 
enzymes in bosentan metabolism
Bosentan metabolic pathways were confirmed as described 
previously.7 Bosentan is metabolized to Ro 48–5033 through 
hydroxylation and to Ro 47–8634 through O-demethylation. 
Ro 47–8634 is further hydroxylated to Ro 64–1056, and Ro 
48–5033 is subsequently metabolized through O-demethylation 
Table 1 Anthropometric, physiologic, and clinical characteristics 
of Caucasian pulmonary arterial hypertension study population 
Number of patients 56
Age (years) 51 ± 13a
Sex M:F (%) 29:71
BMI (kg/m2) 30.8 ± 7.6
History of liver disease (%) 8.9
Bosentan exposure (g/m2) 611 ± 677
CYP2C9 inhibitors (%) 5.3
CYP3A4 inhibitors (%) 8.9
MRP2 inhibitors (%) 3.6
BSEP inhibitors (%) 0
OATP1B1 inhibitors (%) 57.1
OATP1B3 inhibitors (%) 0
BMI, body mass index; BSEP, bile salt export pump; CYP, cytochrome P450; F, female; 
M, male; MRP2, multidrug resistance-associated protein 2; OATP, organic anion–
transporting polypeptides.
aData are presented as either mean ± SD or percentage of total group.
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to form Ro 64–1056. In preliminary experiments, it was con-
firmed that 17, 61, and 11% of bosentan is metabolized in 
60 min by human liver microsomes (HLMs), rCYP3A4, and 
rCYP2C9, respectively. All above-mentioned metabolites were 
formed in HLMs and CYP3A4 reactions, whereas Ro 48–5033 
was the only metabolite formed in CYP2C9 reactions (see 
Supplementary Table S1 online). Other tested rCYP enzymes 
(CYP1A2, CYP2B6, CYP2C8, CYP2C19, and CYP2D6) were 
not implicated in bosentan metabolism (see Supplementary 
Table S1).
Functional activities of CYP2C9*1 (reference), CYP2C9*2, 
and CYP2C9*3 enzymes in metabolism of bosentan to Ro 
48–5033 were evaluated using recombinant enzymes. Both 
CYP2C9*2 and CYP2C9*3 variants had moderately reduced Ro 
48–5033 formation, as compared with CYP2C9*1, at all three 
bosentan concentrations. In particular, ~2.3% of bosentan was 
converted to Ro 48–5033 by CYP2C9*2, ~1.8% by CYP2C9*3, 
and ~2.8% by CYP2C9*1 (Figure 3a).
Assessment of hepatotoxicity of bosentan and its major 
metabolite, Ro 48–5033, was performed in human cultured 
hepatocytes in the presence and absence of 1-aminobenzotria-
zole, a pan-CYP450 inhibitor. In the absence of 1-aminoben-
zotriazole, bosentan and its major metabolite were quickly 
metabolized, and no hepatocyte toxicity was observed (data 
not shown). In the presence of 1-aminobenzotriazole, bosentan 
exhibited hepatotoxicity with an estimated half-maximal inhibi-
tory concentration of ~ 54 µmol/l, whereas its major metabolite 
had no significant effect on hepatocyte viability at the tested 
concentrations (Figure 3b).
Bosentan uptake by OATP1B1 reference and Pro155Thr 
(SLCO1B1 rs11045819) stably transfected HEK293 cells
Bosentan uptake was significantly greater in HEK293 cells sta-
bly expressing the OATP1B1 reference transporter as compared 
with cells expressing empty vector (Figure 4). This difference 
in uptake gradually disappeared with increasing bosentan con-
centrations from 10 µmol/l to 100 µmol/l (data shown in part in 
Table 2 Genetic association analysis for ALT and AST increase 
in 56 pulmonary arterial hypertension patients treated with 
bosentan
ALTa ASTa
Fold changeb P Fold changeb P
Age 1.01 0.53 1.01 0.28
Sex 1.15 0.67 1.12 0.68
BMI 0.96 0.06 0.98 0.13
Hx liver disease 0.87 0.78 1.07 0.87
Bosentan exposure 1.00 0.85 1.00 0.81
Comedications 1.01 0.96 0.90 0.69
ABCC2
 rs717620 0.92 0.74 1.04 0.76
 rs2273697 0.92 0.78 0.81 0.34
 rs1885301 0.94 0.73 1.04 0.82
 rs7910642 1.49 0.33 1.08 0.82
 rs2804402 1.07 0.73 0.98 0.82
ABCB11
 rs2287622 1.19 0.39 1.01 0.92
SLCO1B1
 rs11045819 1.31 0.39 1.31 0.27
 rs2306283 1.16 0.53 1.01 0.99
 rs4149056 1.09 0.76 0.84 0.48
SLCO1B3
 rs7311358 1.28 0.38 1.15 0.52
CYP2C9
 *2/rs1799853 2.18 0.026 1.94 0.015
 *3/rs1057910 0.61 0.21 0.71 0.28
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index.
aUnivariate linear regression was performed, and variants with a P value ≤ 0.2 were 
carried into the multivariate regression analysis adjusted for BMI. The results of 
multivariate regression are presented in the text. bFold change in ALT and AST was 
not normally distributed and was natural log transformed for analysis. Coefficients 
are absolute fold change values. The regression coefficients and the standard 
errors from the transformed data are presented in Supplementary Table S3 
online.
Figure 1 Association between CYP2C9*2 and changes in (a) ALT and (b) AST 
levels in Caucasian PAH patients treated with bosentan. Data are presented as 
mean fold increase from baseline and were analyzed in a multivariate model 
corrected for body mass index (BMI); the P value is indicated. ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; PAH, pulmonary arterial 
hypertension.
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Figure 4). Bosentan transport by the OATP1B1 Pro155Thr vari-
ant was similar to that of the reference transporter (Figure 4).
DISCUSSION
Bosentan significantly improves manageability and prognosis in 
PAH patients,1,8,9 but unfortunately, exposure-dependent liver 
toxicity manifesting in the form of elevated aminotransferases in 
10–12% of treated patients9,10 limits its use. The mechanisms of 
bosentan-induced liver injury have been intensively studied in 
the past decade. Bosentan-induced liver injury has been attrib-
uted at least in part to the accumulation of bile acids in hepato-
cytes as a result of inhibition of BSEP by bosentan.16–18 BSEP 
is an adenosine-5'-triphosphate–dependent transmembrane 
transporter located on the canalicular membrane of hepatocytes. 
It pumps bile acids from hepatocytes into the bile; therefore, 
inhibition of its function results in cholestasis.19 However, in 
in vitro studies, bosentan produced inhibitory effects on BSEP 
at much higher (50–100 µmol/l)16–18 than clinically observed 
plasma concentrations (peak concentration: ~2–4 µmol/l).7 This 
Table 3 Genetic association analysis for drug-induced liver 
injury in 56 pulmonary arterial hypertension patients treated 
with bosentan
ora
or 95% CI  
lower limit
or 95% CI 
upper limit P
Age 0.94 0.86 1.04 0.24
Sex 1.21 0.09 68.2 1.00
BMI 0.96 0.83 1.11 0.62
Hx liver disease 0.00 0.00 18.2 1.00
Bosentan exposure 0.99 0.99 1.00 0.39
Comedications 0.58 0.04 8.61 0.62
ABCC2
 rs717620 1.59 0.11 23.5 0.64
 rs2273697 0.46 0.01 6.18 0.64
 rs1885301 1.86 0.14 103 1.00
 rs7910642 0.00 0.00 8.41 1.00
 rs2804402 0.28 0.02 4.21 0.23
ABCB11
 rs2287622 0.45 0.03 6.74 0.59
SLCO1B1
 rs11045819 4.60 0.30 71.5 0.17
 rs2306283 2.01 0.15 112 1.00
 rs4149056 0.54 0.01 7.26 1.00
SLCO1B3
 rs7311358 0.83 0.02 11.2 1.00
CYP2C9
 *2/rs1799853 ∞ 2.29 ∞ 0.003
 *3/rs1057910 0.00 0.00 8.41 1.00
BMI, body mass index; CI, confidence interval; OR, odds ratio; PAH, pulmonary arterial 
hypertension.
aOdds ratio was calculated by logistic regression for continuous variables and by 
Fisher’s exact test for dichotomous variables.
Figure 2 Association between CYP2C9*2 and drug-induced liver injury 
(DILI) in Caucasian PAH patients treated with bosentan. Data are presented 
as percentage of DILI and non-DILI patients in each allele group and were 
analyzed using Fisher’s exact test; the P value is indicated. PAH, pulmonary 
arterial hypertension.
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Figure 3 Bosentan metabolism by CYP2C9 variant proteins and CYP-
dependent hepatotoxicity. (a) rCYP2C9*1 (reference), rCYP2C9*2, and 
rCYP2C9*3 were incubated with 0.1, 1, and 10 µmol/l bosentan for 0 and 60 min, 
and formation of Ro 48–5033 was quantified by liquid chromatography–
tandem mass spectrometry. Data are presented as percentage of bosentan 
converted to Ro 48–5033 ± SD (N = 3). *P < 0.05 for difference between 
CYP2C9 reference and variants; ‡P < 0.05 for difference between CYP2C9*2 
and CYP2C9*3. (b) Hepatocytes preincubated with 1-aminobenzotriazole 
were treated with increasing concentrations (0–100 µmol/l) of bosentan or 
its metabolite Ro 48–5033 for 48 h. Cell viability was assessed by measuring 
cellular adenosine-5'-triphosphate and glutathione levels. Data are presented 
as percentage of vehicle control. Half-maximal inhibitory concentration (IC50) 
values were calculated using GraphPad Prism software.
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suggests possible effects of additional pharmacokinetic factors, 
which may lead to increased bosentan exposure. Another sug-
gested mechanism of bosentan-induced liver injury involves 
alterations in MRP2-mediated bile salt formation. MRP2 is 
also an adenosine-5'-triphosphate–dependent transmembrane 
transporter located on the canalicular membrane of hepatocytes 
and is largely involved in the efflux of bilirubin, glutathione, 
and glucuronide-conjugated compounds into bile. It has been 
shown that bosentan stimulates MRP2 function,15,17 causing an 
increase in bilirubin and glutathione secretion, which results 
in intermittent uncoupling of lipids from bile salt secretion.15 
Phospholipids normally reduce the cytotoxicity of bile salts; 
thus, uncoupling of lipids from bile salt secretion increases bile 
salt toxicity and may contribute to liver damage.
On the basis of the data implicating MRP2 and BSEP in 
bosentan disposition, we hypothesized that decreased-function 
variants in BSEP might increase a patient’s risk of bosentan-
induced liver damage, whereas reduced-function MRP2 vari-
ants should afford protection against this toxicity. The common 
ABCB11 polymorphism rs2287622, encoding the V444A variant 
of BSEP, was previously shown to be associated with reduced 
hepatic BSEP expression20 and drug-induced cholestasis but 
not with drug-induced hepatocellular injury.21 ABCB11 variants 
may also have a role in intrahepatic cholestasis of pregnancy, 
although this is controversial.22,23 In the current study, an asso-
ciation of rs2287622 with the development of bosentan-induced 
liver toxicity was not observed, possibly due to the small sample 
size. However, considering that bosentan-induced liver injury 
is more hepatocellular in nature,24 perhaps it is not surprising 
that ABCB11 variants did not contribute to risk of this toxicity.
The ABCC2 promoter variant rs717620 has been previously 
shown to be associated with diclofenac-induced hepatotoxicity, 
which is similar in presentation to bosentan-induced liver 
injury.25 ABCC2 haplotypes containing rs717620 were also 
shown to be associated with hepatocellular injury from herbal 
compounds.26 Functional data on ABCC2 promoter variants 
suggest only modest effects on ABCC2 expression,27 and there 
is no consistent report of altered transport by the V417I MRP2 
variant (rs2273697).28,29 In the current study, ABCC2 variants 
were not implicated in bosentan-induced liver injury, suggesting 
involvement of other factors.
Bosentan-induced liver injury has also been attributed to 
mechanisms leading to increased exposure. Inhibition of 
proteins involved in metabolism of bosentan (CYP3A4 and 
CYP2C9) and/or its uptake into the liver (OATP1B1 and 
OATP1B3) results in increased systemic exposure to bosen-
tan and a higher frequency of bosentan-associated adverse 
effects. Inhibitors of CYP3A4 (ketoconazole, itraconazole, and 
ritonavir) and CYP2C9 (fluconazole and amiodarone), as well 
as inhibitors of OATP1B1/1B3 (cyclosporin A, sildenafil, and 
ritonavir), increase the peak concentration and area under 
the concentration–time curve of bosentan in healthy volun-
teers.7,14,30 CYP3A4 accounts for 60% and CYP2C9 for 40% of 
bosentan metabolism in hepatic microsomes,7 and reduction in 
their functionality might be critical in the development of liver 
damage. Assays performed in vitro indicated that hepatotoxic-
ity is attributable to bosentan itself (half-maximal inhibitory 
concentration: ~ 54 µmol/l) and not to its metabolites (Figure 
3b). The transporters OATP1B1 and OATP1B3 are expressed 
on the basolateral membrane of hepatocytes and play a major 
role in transporting bosentan into hepatocytes.11,18 Loss of 
their functionality increases systemic bosentan exposure and 
may also influence nonhepatic adverse effects. On the basis of 
the data strongly supporting involvement of CYP3A4, CYP2C9, 
OATP1B1, and OATP1B3 in bosentan pharmacokinetics, it was 
hypothesized that reduced-function SNPs in these genes will 
confer higher risk of developing bosentan-induced liver injury.
CYP2C9*2 is a common polymorphism associated with a poor 
metabolizer phenotype. This allele encodes the R144C variant 
of CYP2C9, which has ~50% reduced function.31 CYP2C9*2 
has been implicated in reduced clearance of warfarin,32 phe-
nytoin,33 celecoxib,34 and losartan,35 and CYP2C9*2 genotyp-
ing is commonly used in determining initial warfarin dose.32 
The current data suggest that it is the single most important 
factor influencing the risk of bosentan-induced hepatic injury. 
Additional studies will be required to validate its use as a bio-
marker for identifying patients at increased risk of liver toxicity 
from bosentan treatment. Considering the allele distribution 
in major populations, CYP2C9*2 will be most relevant in the 
Caucasian and Hispanic populations, where the minor allele 
frequency for this variant is 10–15%, as compared with African-
American and Asian populations, where it is rarely found (4% 
and 0% minor allele frequencies, respectively).36 A preliminary 
replication in the Hispanic population shows a trend toward 
association of this SNP with elevated ALT/AST levels (ALT: β = 
4.01, P = 0.084; AST: β = 2.48, P = 0.154).
CYP2C9*3 encodes the I359L CYP2C9 variant, which is 
characterized by almost complete loss of function.31,36 This 
Figure 4 Bosentan transport by OATP1B1 reference and Pro155Thr variant 
transporters. Empty vector, OATP1B1 reference, and OATP1B1 Pro155Thr–
expressing cells were incubated with 1, 5, and 10 µmol/l bosentan for 5 min. 
Bosentan uptake was measured and normalized to protein levels. Data are 
presented as mean ± SD (N = 3); P < 0.05.
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polymorphism is less common, having a minor allele frequency 
of 7, 2, and 3% in Caucasian, African-American, and Asian pop-
ulations, respectively.36 It has also been implicated in reduced 
clearance of warfarin,32 phenytoin,33 celecoxib,34 and losartan.35 
In this study, CYP2C9*3 did not show an association with bosen-
tan-induced ALT or AST increase or bosentan-induced liver 
injury, although this might not be evident due to sample size 
limitations. Post hoc power calculations for each SNP confirm 
the limited power of detecting an association with CYP2C9*3 
and other SNPs with relatively low minor allele frequencies 
(see Supplementary Table S3 online). It is plausible that the 
lack of an association of bosentan liver injury with CYP2C9*3 
could also be due to differential metabolism of bosentan by the 
variants, but this is not supported by the similar reductions in 
bosentan metabolism with CYP2C9*2 and CYP2C9*3 recombi-
nant proteins. We also considered the possibility that CYP2C9*2 
is not causative but is tagging a regulatory SNP in the genomic 
region. CYP2C9 promoter polymorphisms become of greater 
importance when induction of CYP2C9 plays a substantial role 
in a drug’s pharmacokinetics.37 Bosentan induces CYP2C9 at 
therapeutic concentrations7 through activation of the pregnane 
X receptor.38 Of note, CYP2C9*2 is in linkage disequilibrium 
(R2 = 0.57) with rs2185570 located downstream of CYP2C9. 
This SNP is located in a transcription factor–binding region 
and DNaseI hypersensitivity cluster, as confirmed by chromatin 
immunoprecipitation–linked DNA sequencing (ChiP-Seq) and 
DNase I hypersensitive sites sequencing (DNase-Seq) data from 
ENCODE, and it has been associated in a genome-wide associa-
tion study with dehydroepiandrosterone sulfate levels. There is 
no evidence that CYP2C9 is directly involved in dehydroepian-
drosterone or dehydroepiandrosterone sulfate metabolism; how-
ever, dehydroepiandrosterone is a known CYP2C9 inducer.39 
CYP2C9*2 is also in linkage disequilibrium (R2 = 0.462) with 
an intronic SNP (rs4086116), that has been associated with 
warfarin40 and acenocumarol dosing.41 Further studies will be 
required to determine whether regulatory SNPs in the CYP2C9 
genomic region might be contributing to bosentan-induced liver 
injury.
Several common polymorphisms in SLCO1B1 have been asso-
ciated with reduced transporter function, altered pharmacoki-
netics, and increased risk of substrate-induced toxicity.42 The 
SLCO1B1 polymorphism encoding the OATP1B1 Pro155Thr 
variant (rs11045819) has been associated with gallstone forma-
tion43 and enhanced lipid-lowering activity of fluvastatin in 
elderly hypercholesterolemic patients.44 In the present study, 
SLCO1B1 polymorphisms were not significantly associated 
with ALT or AST increase, although rs11045819 showed a 
trend toward an association with DILI (Table 3). Functional 
studies confirmed that bosentan is transported by OATP1B1, 
but there was no evidence for reduced function of this variant 
(Figure 4). At higher bosentan concentrations, OATP1B1 trans-
port was not efficient, suggesting that there might be another 
transporter(s) involved. Recent studies suggest that OATP1B3 
has lower affinity but higher capacity for bosentan transport 
as compared with OATP1B1.11 Therefore, OATP1B3 might be 
responsible for this dose-dependent phenomenon in our cell 
model. Functional variants also exist for SLCO1B3,45,46 but the 
current analysis found no evidence that these are important for 
risk of bosentan-induced hepatic injury. The lack of associations 
with SLCO1B1 and SLCO1B3 variants is perhaps not surpris-
ing because reduced-function variants would increase systemic 
exposure and more likely manifest as nonhepatic toxicities.
In summary, CYP2C9*2 was identified as a potential risk 
factor for bosentan-induced liver injury. Additional studies 
are needed to elucidate the molecular basis of this associa-
tion because effects on bosentan metabolism are modest. The 
implications of this finding will require validation in additional 
patients. If validated, this pharmacogenetic marker might be 
useful in the identification of patients at increased risk of this 
serious toxicity and lead to alterations in treatment that would 
avoid this unnecessary risk.
METHODS
Study population. Human investigations were approved by the local 
committee on human research, and all patients gave informed con-
sent to participate. A total of 92 ethnically diverse PAH patients at the 
University of California, San Francisco Medical Center’s Pulmonary 
Hypertension Clinic were recruited into the study during 2003–2008. 
Medical, social, and laboratory data, including age, sex, anthropo-
metric parameters, smoking status, and history of liver disease, were 
collected at the time of enrollment. A blood sample was collected for 
genotyping. Treatment with 125–250 mg bosentan daily was initiated 
and continued for variable time periods depending on the time of 
enrollment and/or withdrawal from the study due to development of 
bosentan-induced liver toxicity. Comedications included phospho-
diesterase-5 inhibitors, prostanoids, calcium channel blockers, anti-
coagulants, diuretics, statins, antifungals, and antimicrobial agents. 
Activities of serum ALT and AST were measured before initiating 
bosentan treatment and then monthly to monitor liver function.
Clinical study design. This pharmacogenetic study was designed as a 
prospective cohort study. First, clinical covariates were defined; these 
included age, sex, body mass index, history of liver disease, bosen-
tan exposure (cumulative dose in mg/m2 of body surface area), and 
comedications that are known inhibitors of CYP3A4 (ritonavir and 
verapamil), CYP2C9 (fluconazole and metronidazole), OATP1B1 
(sildenafil and statins), OATP1B3 (statins and valsartan), MRP2 (rito-
navir and statins), and BSEP (rifampicin). Next, genetic covariates were 
selected. A literature search for reduced-function SNPs was focused 
on six genes (CYP3A4, CYP2C9, SLCO1B1, SLCO1B3, ABCB11, and 
ABCC2) encoding proteins involved in bosentan pharmacokinetics. A 
total of 15 SNPs were selected (see Supplementary Table S2 online).
Two types of outcomes for testing genetic associations were estab-
lished. Outcome 1 was defined as the fold increase in ALT and AST 
activities from time of enrollment to the end of the study or to the time of 
bosentan discontinuation due to liver toxicity. Outcome 1 was expressed 
as a continuous variable, logarithmically transformed for analysis. Out-
come 2 was classification of DILI, defined as a threefold increase of either 
ALT or AST above the upper limit of normal at any point in the study (n 
= 4). Outcome 2 was expressed as a binary variable. In addition to clas-
sifying DILI based on liver enzyme elevations, the data were evaluated 
with the Roussel Uclaf Causality Assessment Method (RUCAM).47,48 
RUCAM was performed by two independent individuals, and all Cauca-
sian cases previously classified as DILI cases on the basis of liver enzyme 
elevations received RUCAM scores of “possible (n = 3)” or “probable (n 
= 1),” increasing confidence in the assignment of cases. Data on rechal-
lenges were largely absent. One clinical team cared for these pulmonary 
hypertension patients; initially, two patients were rechallenged, and both 
redeveloped an elevation in liver function test. Based on knowledge that 
DILI was a recognized complication of the drug, rechallenges were 
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 discontinued with the arrival of the clinical availability of a newer agent 
with reduced risk of liver injury.
Genotyping. DNA samples from 92 PAH patients were extracted 
and genotyped on the DMET chip (Affimetrix, DMET Early Access 
Program). The following SNPs were extracted for analysis: CYP2C9 
(CYP2C9*2/rs1799853 and CYP2C9*3/rs1057910), SLCO1B1 
(rs11045819, rs2306283, and rs4149056), SLCO1B3 (rs414917 and 
rs7311358), ABCB11 (rs2287622), and ABCC2 (rs717620, rs2273697, 
rs8187692, and rs17222723). In addition, ABCC2 SNPs (rs1885301, 
rs7910642, and rs2804402) not present on the chip were genotyped by 
direct sequencing at the University of California, San Francisco genet-
ics core facility.
Genetic association analysis. To avoid potential spurious associa-
tions as a result of population substructure and admixture, analy-
sis was restricted to 56 Caucasian PAH patients. Selected SNPs were 
checked for deviation from Hardy–Weinberg equilibrium and filtered 
for minor allele frequency >5% and linkage disequilibrium <0.8. After 
filtering, 12 SNPs in five genes—CYP2C9 (rs1799853 and rs1057910), 
SLCO1B1 (rs11045819, rs2306283, and rs4149056), SLCO1B3 
(rs7311358), ABCB11 (rs2287622), and ABCC2 (rs717620, rs2273697, 
rs1885301, rs2804402, and rs7910642)—were analyzed for associa-
tions with changes in AST and ALT activity (Outcome 1) and occur-
rence of DILI (Outcome 2) using linear and logistic regression analyses 
or Fisher’s exact test. An additive inheritance model was applied in the 
linear regression analysis, and a dominant inheritance model was used 
for the Fisher’s exact test. Linear regression analysis was performed in 
two steps. First, each clinical covariate and each SNP were tested for 
associations in univariate analyses, and those with P < 0.2 were car-
ried into multivariate analyses. Multivariate models were adjusted 
for significant clinical covariates with inclusion of SNPs from step 1. 
Associations with P < 0.05 in multivariate analyses were considered 
significant. A multivariate analysis for genetic associations with DILI 
was not performed due to the small size of the cohort and the DILI 
group. Post hoc power calculations for the genetic associations with 
ALT and AST were conducted for effect sizes equal to the observed 
effect estimates using the power.t.test function in R v. 3.0.1. Post hoc 
power for Fisher’s exact tests of the association of genetic carrier status 
with DILI were conducted using the power.fisher.test function from 
the statmod library in R v. 3.0.1 with 10,000 simulated data sets.
Hepatocyte toxicity assay. The assay was performed as described pre-
viously.49 Briefly, human hepatocytes were plated at 0.3 × 105 cells/
well in collagen I-coated plates. Four hours after plating, cells were 
preincubated for 16 h with 0.5 mmol/l 1-aminobenzotriazole (Sigma-
Aldrich, St Louis, MO). Subsequently, medium was replaced with 
fresh medium containing bosentan, its metabolite Ro 48–5033, or 
chlorpromazine as a positive control at varying concentrations (0–100 
µmol/l) and incubated for an additional 48 h. Dimethyl sulfoxide was 
used as the negative control. At the end of incubation, cell viability 
was assessed by measuring adenosine-5'-triphosphate levels using 
CellTiter-Glo and cellular glutathione levels using GSH-Glo following 
the manufacturer’s protocols (Promega, Madison, WI). Data are pre-
sented as mean percentage of control ± SD of triplicate experiments. 
Half-maximal inhibitory concentration values were calculated using 
Graph Pad Prism (v. 5).
Enzyme kinetic studies with HLMs and recombinant CYP2C9*1, 
CYP2C9*2, and CYP2C9*3 enzymes. Bosentan was purchased from 
Waterstone Technology (Carmel, IN). HLMs and rCYP450 reference 
enzymes were purchased from BD Biosciences (San Jose, CA). The 
CYP2C9*1, CYP2C9*2, and CYP2C9*3 enzymes for functional com-
parison experiments were purchased from Cypex Limited (Dundee, 
UK). Enzyme activities were measured by parent drug disappearance 
and metabolite formation in incubations with 0.1 µmol/l, 1 µmol/l, and 
10 µmol/l bosentan. All incubations were performed in 100 mmol/l 
phosphate buffer (pH 7.4). The final protein concentration was 0.5 mg/
ml in HLM incubations, and the enzyme concentration was 40 pmol/
ml in incubations with recombinant CYP2C9 enzymes. All incuba-
tions were performed at 37 °C for 60 min. Reactions were initiated by 
adding nicotinamide adenine dinucleotide phosphate (final concen-
tration of 10 mmol/l) and were terminated by adding a 3X volume of 
acetonitrile. Samples were vortexed for 5 min before centrifugation at 
2,690g for 10 min. The supernatant was transferred to new tubes and 
dried down at room temperature with a Labconco Centrivap DNA 
Concentrator. It was then reconstituted with a water:acetonitrile 
mixture (2:1), followed by vortexing for 5 min and centrifugation at 
11,000g for 10 min. The supernatant was analyzed by liquid chroma-
tography–tandem mass spectrometry. Negative controls consisting of 
incubation matrix without substrate were incubated under identical 
conditions. Data are presented as mean ± SD of triplicate experiments. 
Statistical analysis was performed using two-way analysis of variance; 
P < 0.05 was considered significant.
Functional assay of bosentan uptake by OATP1B1 reference and 
 variant proteins. Stable cell lines expressing the OATP1B1 reference 
and variant transporters have been described elsewhere.50 Uptake 
assays were performed in triplicate on poly-D-lysine-coated 48-well 
plates (BD Biosciences, CA). Empty vector, OATP1B1 reference, and 
the Pro155Thr variant (rs11045819, C463A)–expressing cells were 
seeded at 1.5 × 105 cells/well in complete Dulbecco’s modified Eagle 
medium supplemented with 10% fetal bovine serum. On the follow-
ing day, medium was supplemented with 5 mmol/l sodium butyrate, 
and cells were incubated for another 24 h. Twenty-four hours later, 
the cells were washed with warm Krebs–Henseleit buffer and incu-
bated with 1, 5, 10, 25, 50, or 100 µmol/l bosentan in Krebs–Henseleit 
buffer for 5 min at 37 °C. After accumulation, cells were washed twice 
with ice-cold Krebs–Henseleit buffer and were lysed with a solu-
tion of 10% sodium dodecyl sulfate and 1 N NaOH. Bosentan was 
extracted with two volumes of acetonitrile. An aliquot of the cell 
lysate was used to determine protein concentration with a bicin-
choninic acid protein assay kit (Pierce Biotechnology, IL), and bosen-
tan levels were normalized to total protein concentrations. Data are 
presented as mean ± SD of triplicate experiments. Statistical analysis 
was performed using two-way analysis of variance; P < 0.05 was con-
sidered significant.
Chromatographic and mass spectrometric conditions for measuring 
bosentan and its metabolites. Liquid chromatography–mass spec-
trometry analysis was conducted using a Thermo LTQ XL coupled to 
an ultra-high-pressure liquid chromatography device (Accela Pump), 
an Accela autosampler, and an Accela photodiode array detector 
(San Jose, CA). The mass spectrometric conditions were set as follows: 
positive mode: electrospray ionization, capillary voltage: 16 V, source 
voltage: 4.5 kV, tube lens voltage: 95 V, capillary temperature: 350 °C, 
sheath gas flow: 57 units, auxiliary gas flow: 24 units, and sweep gas 
flow: 5 units, using full-scan, MSn, and targeted MSn scan modes. The 
high-pressure liquid chromatography column used for both systems 
was a Thermo Hypersil Gold C18 (100 × 2.1 mm, 1.9 µm; Thermo 
Scientific, Pittsburgh, PA). The solvent system consisted of solvent A 
(0.1% formic acid in water) and solvent B (0.1% formic acid in acetoni-
trile). Solvent B was delivered initially at 5%, held for 1 min, increased 
to 95% via a 25-min gradient, then decreased back to 5% at 26 min, and 
equilibrated for 4 min at a flow rate of 400 µl/min and a total run time 
of 30 min. The injection volume was 20 µl.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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